In ₹ Crore except Per Share Latest Annual | PARNAXLAB FY25 | BPLPHARMA FY23 | JENBURPH FY26 | KPL FY24 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 105.74× | ◆ 37.02× | — | — | 37.02× +186% | |
| Growth | ||||||
| Revenue CAGR 3Y | -0.61% | — | ◆ 7.26% | — | 7.26% -108% | |
| Revenue CAGR 5Y | -1.78% | — | ◆ 9.07% | — | 9.07% -120% | |
| Net Income CAGR 3Y | — | — | 12.18% | — | 12.18% | |
| Profitability | ||||||
| EBITDA Margin | 17.61% | 9.80% | ◆ 23.81% | 21.69% | 21.69% -19% | |
| Net Income Margin | — | 11.16% | ◆ 20.59% | — | 15.88% | |
| Return on Common Equity | — | 12.74% | — | — | 12.74% | |
| Return on Capital Employed | — | — | — | 19.18% | 19.18% | |
| Return on Assets | — | 7.90% | ◆ 15.37% | — | 11.63% | |
| Credit & Quality | ||||||
| Total Debt/Equity | — | ◆ 0.04× | — | 0.43× | 0.23× | |
| Interest Coverage | ◆ 49.06× | 7.10× | — | 4.54× | 5.82× +743% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹7 Cr | ₹218 Cr | ₹169 Cr | ₹307 Cr | ₹218 Cr -97% | |
| Net Income | — | ₹24.3 Cr | ₹34.7 Cr | — | ₹29.5 Cr | |
| Total Assets | ₹24.7 Cr | ₹308 Cr | ₹226 Cr | ₹398 Cr | ₹308 Cr -92% | |
| EPS | ₹1.21 | ₹42.14 | — | — | ₹42.14 -97% | |